| Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities TK Kim, EN Vandsemb, RS Herbst, L Chen Nature Reviews Drug Discovery 21 (7), 529-540, 2022 | 234 | 2022 |
| Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade R Yang, S Elsaadi, K Misund, P Abdollahi, EN Vandsemb, SH Moen, ... Journal for immunotherapy of cancer 8 (1), 2020 | 106 | 2020 |
| Phosphatase of regenerating liver 3 (PRL-3) is overexpressed in human prostate cancer tissue and promotes growth and migration EN Vandsemb, H Bertilsson, P Abdollahi, Ø Størkersen, TK Våtsveen, ... Journal of translational medicine 14, 1-11, 2016 | 38 | 2016 |
| The phosphatase of regenerating liver-3 (PRL-3) is important for IL-6-mediated survival of myeloma cells TS Slørdahl, P Abdollahi, EN Vandsemb, C Rampa, K Misund, ... Oncotarget 7 (19), 27295, 2016 | 38 | 2016 |
| Src family kinases are regulated in multiple myeloma cells by phosphatase of regenerating liver-3 P Abdollahi, EN Vandsemb, MA Hjort, K Misund, T Holien, AM Sponaas, ... Molecular Cancer Research 15 (1), 69-77, 2017 | 25 | 2017 |
| Phosphatase of regenerating liver‐3 regulates cancer cell metabolism in multiple myeloma P Abdollahi, EN Vandsemb, S Elsaadi, LM Røst, R Yang, MA Hjort, ... The FASEB Journal 35 (3), e21344, 2021 | 24 | 2021 |
| Targeting phosphoglycerate dehydrogenase in multiple myeloma S Elsaadi, I Steiro, P Abdollahi, EN Vandsemb, R Yang, TS Slørdahl, ... Experimental Hematology & Oncology 10, 1-13, 2021 | 21 | 2021 |
| Phosphatase of regenerating liver-3 is expressed in acute lymphoblastic leukemia and mediates leukemic cell adhesion, migration and drug resistance MA Hjort, P Abdollahi, EN Vandsemb, MH Fenstad, B Lund, TS Slørdahl, ... Oncotarget 9 (3), 3549, 2017 | 21 | 2017 |
| Phosphatase of regenerating liver-3 (PRL-3) is overexpressed in classical Hodgkin lymphoma and promotes survival and migration MA Hjort, H Hov, P Abdollahi, EN Vandsemb, UM Fagerli, B Lund, ... Experimental Hematology & Oncology 7, 1-13, 2018 | 14 | 2018 |
| PRL‐3 induces a positive signaling circuit between glycolysis and activation of STAT1/2 EN Vandsemb, MB Rye, IJ Steiro, S Elsaadi, TB Rø, TS Slørdahl, ... The FEBS Journal 288 (23), 6700-6715, 2021 | 13 | 2021 |
| Phosphatases of regenerating liver are key regulators of metabolism in cancer cells–role of Serine/Glycine metabolism P Abdollahi, EN Vandsemb, M Børset Current Opinion in Clinical Nutrition & Metabolic Care 25 (1), 50-55, 2022 | 10 | 2022 |
| PD-1H/VISTA mediates immune evasion in acute myeloid leukemia TK Kim, X Han, Q Hu, EN Vandsemb, CM Fielder, J Hong, KW Kim, ... The Journal of clinical investigation 134 (3), 2024 | 8 | 2024 |
| Will deeper characterization of the landscape of immune checkpoint molecules in acute myeloid leukemia bone marrow lead to improved therapeutic targeting? EN Vandsemb, TK Kim, AM Zeidan Cancer 125 (9), 1410-1413, 2019 | 8 | 2019 |
| Bystander Memory T Cells and IMiD/Checkpoint Therapy in Multiple Myeloma: A Dangerous Tango? AM Sponaas, A Waage, EN Vandsemb, K Misund, M Børset, A Sundan, ... Frontiers in Immunology 12, 636375, 2021 | 6 | 2021 |
| Highly expressed genes in multiple myeloma cells–what can they tell us about the disease? M Børset, S Elsaadi, EN Vandsemb, ES Hess, IJ Steiro, ... European Journal of Haematology 109 (1), 31-40, 2022 | 5 | 2022 |
| Inhibition of cytosolic phospholipase A2α induces apoptosis in multiple myeloma cells N Mahammad, FJ Ashcroft, AJ Feuerherm, S Elsaadi, EN Vandsemb, ... Molecules 26 (24), 7447, 2021 | 4 | 2021 |
| The serine protease matriptase inhibits migration and proliferation in multiple myeloma cells I Steiro, EN Vandsemb, S Elsaadi, K Misund, AM Sponaas, M Børset, ... Oncotarget 13, 1175, 2022 | 3 | 2022 |
| TAK1-inhibitors did not reduce disease burden in a Vκ* MYC model of multiple myeloma E Håland, IN Moen, EN Vandsemb, KK Starheim BMC Research Notes 15 (1), 352, 2022 | 1 | 2022 |
| P-079: Altered composition of CD8 T cells subsets over time in the bone marrow of multiple myeloma patients with long-and short-term disease control A Behsen, E Vandsemb, A Waage, TS Slørdahl, AM Sponaas, K Misund Clinical Lymphoma Myeloma and Leukemia 22, S78-S79, 2022 | 1 | 2022 |
| A patient with minimal myeloma treatment who survived for 20 years AD Behsen, EN Vandsemb, TS Slørdahl, H Hjorth-Hansen, ... Haematologica 109 (4), 1301, 2023 | | 2023 |
